Ken-ichi Inui

List of Publications by Year
in descending order

154	11,876	18436 62	29081 104
papers	citations	h-index	g-index

155	155	155	7749
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Gene Expression Levels and Immunolocalization of Organic Ion Transporters in the Human Kidney. Journal of the American Society of Nephrology: JASN, 2002, 13, 866-874.	3.0	450
2	Cellular and molecular aspects of drug transport in the kidney. Kidney International, 2000, 58, 944-958.	2.6	404
3	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochemical Pharmacology, 2007, 74, 359-371.	2.0	369
4	Identification and Functional Characterization of a New Human Kidneyâ€“Specific H+/Organic Cation Antiporter, Kidney-Specific Multidrug and Toxin Extrusion 2. Journal of the American Society of Nephrology: JASN, 2006, 17, 2127-2135.	3.0	348
5	cDNA Cloning and Functional Expression of a Novel Rat Kidney Organic Cation Transporter, OCT2. Biochemical and Biophysical Research Communications, 1996, 224, 500-507.	1.0	335
6	Metformin is a Superior Substrate for Renal Organic Cation Transporter OCT2 rather than Hepatic OCT1. Drug Metabolism and Pharmacokinetics, 2005, 20, 379-386.	1.1	313
7	Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1â€“3 and Multidrug and Toxin Extrusion Family). Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 879-886.	1.3	300
8	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3569-3574.	3.3	261
9	Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochemical Pharmacology, 2007, 74, 477-487.	2.0	217
10	Immuno-Localization of H+/Peptide Cotransporter in Rat Digestive Tract. Biochemical and Biophysical Research Communications, 1996, 220, 848-852.	1.0	213
11	Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein*. Clinical Pharmacology and Therapeutics, 1998, 64, 123-128.	2.3	201
12	C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics and Genomics, 2002, 12, 451-457.	5.7	186
13	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics and Genomics, 2004, 14, 471-478.	5.7	182
14	Creatinine Transport by Basolateral Organic Cation Transporter hOCT2 in the Human Kidney. Pharmaceutical Research, 2004, 21, 976-981.	1.7	180
15	Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochemical Pharmacology, 2010, 80, 1762-1767.	2.0	180
16	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, 112, 184-198.		173
17	Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 185-191.	1.3	170
18	(Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Peptide Transporters: Structure, Function, Regulation and Application for Drug Delivery. Current Drug Metabolism, 2004, 5, 85-94.	0.7	167

#	Article	IF	Citations
19	Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin. Molecular Pharmacology, 2009, 75, 1280-1286.	1.0	162
20	Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney. AAPS Journal, 2013, 15, 581-588.	2.2	162
21	Metformin Transport by Renal Basolateral Organic Cation Transporter hOCT2. Pharmaceutical Research, 2005, 22, 255-259.	1.7	156
22	Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. British Journal of Pharmacology, 2011, 164, 1817-1825.	2.7	155
23	Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles. Biochimica Et Biophysica Acta - Biomembranes, 1984, 773, 113-124.	1.4	152
24	Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochemical Pharmacology, 2005, 70, 1823-1831.	2.0	152
25	Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Letters, 1999, 461, 339-342.	1.3	148
26	Organic cation transporter OCT/SLC22A and H+/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochemical Pharmacology, 2011, 81, 563-568.	2.0	148
27	Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney International, 2002, 62, 514-524.	2.6	132
28	Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochemical Pharmacology, 2008, 75, 1689-1696.	2.0	131
29	Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. American Journal of Physiology - Cell Physiology, 2008, 295, C632-C641.	2.1	126
30	Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Letters, 2000, 473, 173-176.	1.3	125
31	Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenetics and Genomics, 2006, 16, 119-127.	0.7	125
32	Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 950-955.	0.5	125
33	Novel riboflavin transporter family RFVT/SLC52: Identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. Molecular Aspects of Medicine, 2013, 34, 693-701.	2.7	125
34	Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Letters, 1998, 438, 321-324.	1.3	124
35	A Novel Approach to Therapeutic Angiogenesis for Patients With Critical Limb Ischemia by Sustained Release of Basic Fibroblast Growth Factor Using Biodegradable Gelatin Hydrogel An Initial Report of the Phase I-IIa Study. Circulation Journal, 2007, 71, 1181-1186.	0.7	121
36	Identification and Comparative Functional Characterization of a New Human Riboflavin Transporter hRFT3 Expressed in the Brain. Journal of Nutrition, 2010, 140, 1220-1226.	1.3	121

#	Article	IF	Citations
37	Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clinical Pharmacology and Therapeutics, 2001, 69, 308-316.	2.3	120
38	Molecular Cloning, Functional Characterization and Tissue Distribution of Rat H+/Organic Cation Antiporter MATE1. Pharmaceutical Research, 2006, 23, 1696-1701.	1.7	120
39	cDNA Cloning, Functional Characterization, and Tissue Distribution of an Alternatively Spliced Variant of Organic Cation Transporter hOCT2 Predominantly Expressed in the Human Kidney. Journal of the American Society of Nephrology: JASN, 2002, 13, 1703-1710.	3.0	114
40	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochemical Pharmacology, 2005, 70, 1104-1113.	2.0	114
41	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters. British Journal of Pharmacology, 2021, 178, S412-S513.	2.7	114
42	Peptide transporter in the rat small intestine: ultrastructural localization and the effect of starvation and administration of amino acids. The Histochemical Journal, 1999, 31, 169-174.	0.6	103
43	Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial. BMC Medicine, 2010, 8, 76.	2.3	96
44	Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. Human Mutation, 2011, 32, E1976-E1984.	1.1	96
45	Expression Levels of Renal Organic Anion Transporters (OATs) and Their Correlation with Anionic Drug Excretion in Patients with Renal Diseases. Pharmaceutical Research, 2004, 21, 61-67.	1.7	95
46	Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2. Pflugers Archiv European Journal of Physiology, 2000, 440, 679-684.	1.3	91
47	UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. International Journal of Clinical Oncology, 2009, 14, 136-142.	1.0	90
48	Methotrexate-Loxoprofen Interaction: Involvement of Human Organic Anion Transporters hOAT1 and hOAT3. Drug Metabolism and Pharmacokinetics, 2004, 19, 369-374.	1.1	86
49	Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochemical Pharmacology, 2008, 76, 894-903.	2.0	86
50	Gene expression and regulation of drug transporters in the intestine and kidney. Biochemical Pharmacology, 2007, 73, 440-449.	2.0	83
51	Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics. Drug Metabolism and Pharmacokinetics, 2012, 27, 631-639.	1.1	82
52	Identification of the histidine residues involved in substrate recognition by a rat H+/peptide cotransporter, PEPT1. FEBS Letters, 1996, 394, 196-200.	1.3	81
53	mRNA distribution and membrane localization of the OAT-K1 organic anion transporter in rat renal tubules. FEBS Letters, 1997, 407, 127-131.	1.3	81
54	Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. Journal of Human Genetics, 2009, 54, 40-46.	1.1	79

#	Article	IF	Citations
55	Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochemical Pharmacology, 2009, 78, 1263-1271.	2.0	79
56	Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. Biochemical Pharmacology, 2005, 70, 1756-1763.	2.0	78
57	Multidrug and toxin extrusion family SLC47: Physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Molecular Aspects of Medicine, 2013, 34, 661-668.	2.7	78
58	Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer. Clinical Pharmacokinetics, 2013, 52, 593-609.	1.6	77
59	Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clinical Pharmacology and Therapeutics, 2005, 78, 168-181.	2.3	75
60	Differential localization of organic cation transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney proximal tubules. Histochemistry and Cell Biology, 2000, 114, 175-180.	0.8	74
61	Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. American Journal of Physiology - Renal Physiology, 2007, 292, F593-F598.	1.3	72
62	Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharmaceutical Research, 1998, 15, 1609-1613.	1.7	70
63	Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. , 2015, 152, 125-134.		67
64	Hepatitis C Virus-related Cirrhosis is a Major Determinant of the Expression Levels of Hepatic Drug Transporters. Drug Metabolism and Pharmacokinetics, 2010, 25, 190-199.	1.1	66
65	Transport Characteristics of a Novel Peptide Transporter 1 Substrate, Antihypotensive Drug Midodrine, and Its Amino Acid Derivatives. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 455-460.	1.3	62
66	Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. European Journal of Pharmacology, 2012, 696, 143-154.	1.7	61
67	Altered Pharmacokinetics of Cationic Drugs Caused by Down-Regulation of Renal Rat Organic Cation Transporter 2 (Slc22a2) and Rat Multidrug and Toxin Extrusion 1 (Slc47a1) in Ischemia/Reperfusion-Induced Acute Kidney Injury. Drug Metabolism and Disposition, 2008, 36, 649-654.	1.7	57
68	Precise comparison of protein localization among OCT, OAT, and MATE in human kidney. Journal of Pharmaceutical Sciences, 2013, 102, 3302-3308.	1.6	56
69	ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Annals of Oncology, 2010, 21, 1382-1383.	0.6	51
70	Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins. Pharmaceutical Research, 2014, 31, 136-147.	1.7	51
71	Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clinical Pharmacology and Therapeutics, 2006, 79, 90-102.	2.3	50
72	Reduced Renal Clearance of a Zwitterionic Substrate Cephalexin in Mate1-Deficient Mice. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 651-656.	1.3	49

#	Article	IF	Citations
73	Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochemical Pharmacology, 2009, 77, 1429-1436.	2.0	48
74	Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenetics and Genomics, 2010, 20, 135-138.	0.7	48
75	Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis. Journal of Thoracic Oncology, 2010, 5, 601-605.	0.5	47
76	Genetic variant Arg57His in human H+/peptide cotransporter 2 causes a complete loss of transport function. Biochemical and Biophysical Research Communications, 2004, 316, 416-420.	1.0	44
77	Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. Biochemical Pharmacology, 2007, 73, 1482-1490.	2.0	44
78	Carrier-mediated transport of amino-cephalosporins by brush border membrane vesicles isolated from rat kidney cortex. Biochemical Pharmacology, 1983, 32, 621-626.	2.0	42
79	Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. Journal of Human Genetics, 2008, 53, 607-614.	1.1	42
80	Cellular and molecular mechanisms of renal tubular secretion of organic anions and cations. Clinical and Experimental Nephrology, 1998, 2, 100-108.	0.7	41
81	Tacrolimus Therapy as an Alternative to Thiopurines for Maintaining Remission in Patients With Refractory Ulcerative Colitis. Journal of Clinical Gastroenterology, 2011, 45, 526-530.	1.1	41
82	Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney International, 2001, 60, 1058-1068.	2.6	40
83	Upregulation of H⁺-peptide cotransporter PEPT2 in rat remnant kidney. American Journal of Physiology - Renal Physiology, 2001, 281, F1109-F1116.	1.3	39
84	Recent Advances in Structural Biology of Peptide Transporters. Current Topics in Membranes, 2012, 70, 257-274.	0.5	39
85	Functional analysis of rat renal organic anion transporter OAT-K1: bidirectional methotrexate transport in apical membrane. FEBS Letters, 1999, 459, 128-132.	1.3	38
86	Forecasting of Blood Tacrolimus Concentrations Based on the Bayesian Method in Adult Patients Receiving Living-Donor Liver Transplantation. Clinical Pharmacokinetics, 2003, 42, 1161-1178.	1.6	38
87	Distinct Inhibitory Effects of Tacrolimus and Cyclosporin A on Calcineurin Phosphatase Activity. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 816-825.	1.3	38
88	Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1. American Journal of Physiology - Renal Physiology, 2007, 293, F1564-F1570.	1.3	38
89	Impact of IntestinalCYP2C19Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients. Drug Metabolism and Disposition, 2009, 37, 821-826.	1.7	38
90	Distribution characteristics of levofloxacin and grepafloxacin in rat kidney. Pharmaceutical Research, 1999, 16, 534-539.	1.7	37

#	Article	IF	Citations
91	Lansoprazoleâ€"Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism. Annals of Pharmacotherapy, 2004, 38, 791-794.	0.9	36
92	Pharmacokinetic Significance of Renal OAT3 (SLC22A8) for Anionic Drug Elimination in Patients with Mesangial Proliferative Glomerulonephritis. Pharmaceutical Research, 2005, 22, 2016-2022.	1.7	35
93	The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma. Therapeutic Drug Monitoring, 2014, 36, 310-316.	1.0	35
94	Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. American Journal of Physiology - Renal Physiology, 2008, 295, F247-F252.	1.3	34
95	Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. Pharmaceutical Research, 1996, 13, 1073-1077.	1.7	33
96	Identification of Essential Histidine and Cysteine Residues of the H+/Organic Cation Antiporter Multidrug and Toxin Extrusion (MATE). Molecular Pharmacology, 2007, 71, 1487-1493.	1.0	33
97	Human NPC1L1 Expression is Positively Regulated by PPARÎ±. Pharmaceutical Research, 2011, 28, 405-412.	1.7	33
98	Computational modelling of H+-coupled peptide transport via human PEPT1. Journal of Physiology, 2005, 565, 429-439.	1.3	30
99	A Case of Radiation Recall Pneumonitis Induced by Erlotinib, Which Can be Related to High Plasma Concentration. Journal of Thoracic Oncology, 2010, 5, 924-925.	0.5	30
100	Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity. Biochemical Pharmacology, 2013, 85, 570-582.	2.0	30
101	Effects of glibenclamide on glycylsarcosine transport by the rat peptide transporters PEPT1 and PEPT2. British Journal of Pharmacology, 1999, 128, 1159-1164.	2.7	29
102	Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells. American Journal of Physiology - Renal Physiology, 2000, 278, G563-G569.	1.6	29
103	Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5. Drug Metabolism and Pharmacokinetics, 2008, 23, 134-138.	1.1	29
104	Cisplatin-induced toxicity in LLC-PK1 kidney epithelial cells: role of basolateral membrane transport. Toxicology Letters, 1999, 106, 229-235.	0.4	28
105	Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. Journal of Human Genetics, 2004, 49, 40-45.	1.1	28
106	Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharmaceutical Research, 1998, 15, 734-738.	1.7	26
107	mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochemical Pharmacology, 2010, 79, 67-76.	2.0	25
108	Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 886-891.	1.4	25

#	Article	IF	Citations
109	Interactions of Fluoroquinolone Antibacterials, DX-619 and Levofloxacin, with Creatinine Transport by Renal Organic Cation Transporter hOCT2. Drug Metabolism and Pharmacokinetics, 2006, 21, 432-436.	1.1	24
110	Rat Renal Organic Anion Transporter rOAT1 Mediates Transport of Urinary-Excreted Cephalosporins, but not of Biliary-Excreted Cefoperazone. Drug Metabolism and Pharmacokinetics, 2002, 17, 125-129.	1.1	23
111	Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: Twice daily vs. once daily dosing. Liver Transplantation, 2006, 12, 292-300.	1.3	22
112	Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. International Journal of Clinical Oncology, 2010, 15, 512-514.	1.0	22
113	Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. Pharmaceutical Research, 1997, 14, 508-511.	1.7	21
114	A Retrospective Analysis of Vancomycin Pharmacokinetics in Japanese Cancer and Non-cancer Patients Based on Routine Trough Monitoring Data. Biological and Pharmaceutical Bulletin, 2009, 32, 99-104.	0.6	21
115	Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Nonâ€“Small-Cell Lung Cancer With Pleural Effusion. Clinical Lung Cancer, 2011, 12, 307-312.	1.1	21
116	Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. Pharmacogenetics and Genomics, 2009, 19, 647-656.	0.7	20
117	Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice. Scientific Reports, 2016, 6, 27557.	1.6	20
118	A Transient Increase of Calcineurin Phosphatase Activity in Living-Donor Kidney Transplant Recipients with Acute Rejection. Drug Metabolism and Pharmacokinetics, 2010, 25, 411-417.	1.1	19
119	Developmental trajectory of intestinal <scp>MDR1/ABCB1</scp> mRNA expression in children. British Journal of Clinical Pharmacology, 2014, 77, 910-912.	1.1	19
120	Association between CYP3A5 Genotypes in Graft Liver and Increase in Tacrolimus Biotransformation from Steroid Treatment in Living-donor Liver Transplant Patients. Drug Metabolism and Pharmacokinetics, 2014, 29, 83-89.	1.1	19
121	Kinetic analysis of tetraethylammonium transport in the kidney epithelial cell line, LLC-PK1. Pharmaceutical Research, 1997, 14, 1236-1240.	1.7	18
122	MDR1 Haplotypes Conferring an Increased Expression of Intestinal CYP3A4 Rather than MDR1 in Female Living-Donor Liver Transplant Patients. Pharmaceutical Research, 2009, 26, 1590-1595.	1.7	18
123	Effects of Metabolic Acidosis on Expression Levels of Renal Drug Transporters. Pharmaceutical Research, 2011, 28, 1023-1030.	1.7	18
124	Developmental expression of renal organic anion transporters in rat kidney and its effect on renal secretion of phenolsulfonphthalein. American Journal of Physiology - Renal Physiology, 2012, 302, F1640-F1649.	1.3	18
125	Transport characteristics of ceftibuten, a new cephaloporin antibiotic, via the apical H+/dipeptide cotransport system in human intestinal cell line Caco-2: regulation by cell growth. Pharmaceutical Research, 1995, 12, 1483-1487.	1.7	17
126	Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. European Journal of Clinical Pharmacology, 2012, 68, 259-266.	0.8	17

#	Article	IF	Citations
127	Relation between mRNA Expression Level of Multidrug Resistance 1/ABCB1 in Blood Cells and Required Level of Tacrolimus in Pediatric Living-Donor Liver Transplantation. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 610-616.	1.3	16
128	Distinct transport characteristics of basolateral peptide transporters between MDCK and Caco-2 cells. Pflugers Archiv European Journal of Physiology, 2001, 443, 31-37.	1.3	15
129	Gene expression variance based on random sequencing in rat remnant kidney. Kidney International, 2004, 66, 29-45.	2.6	15
130	Required Transient Dose Escalation of Tacrolimus in Living-Donor Liver Transplant Recipients with High Concentrations of a Minor Metabolite M-II in Bile. Drug Metabolism and Pharmacokinetics, 2008, 23, 313-317.	1.1	15
131	Renal Tubular Secretion of Varenicline by Multidrug and Toxin Extrusion (MATE) Transporters. Drug Metabolism and Pharmacokinetics, 2012, 27, 563-569.	1.1	15
132	Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats. American Journal of Physiology - Renal Physiology, 2010, 298, F923-F934.	1.3	12
133	Effect of Intestinal and Hepatic First-pass Extraction on the Pharmacokinetics of Everolimus in Rats. Drug Metabolism and Pharmacokinetics, 2008, 23, 469-475.	1.1	11
134	Decreased transport of p-aminohippurate in renal basolateral membranes isolated from rats with acute renal failure. Pharmaceutical Research, 1989, 06, 954-957.	1.7	9
135	Clâ^'-dependent upregulation of human organic anion transporters: different effects on transport kinetics between hOAT1 and hOAT3. American Journal of Physiology - Renal Physiology, 2007, 293, F391-F397.	1.3	8
136	Renal Excretion of Vancomycin in Rats with Acute Renal Failure. Journal of Pharmacy and Pharmacology, 2011, 49, 154-157.	1.2	8
137	Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury. Cancer Chemotherapy and Pharmacology, 2015, 75, 1191-1197.	1.1	8
138	Effects of tacrolimus and cyclosporin A on peptide transporter PEPT1 in Caco-2 cells. Pharmaceutical Research, 2001, 18, 713-717.	1.7	7
139	Distinct transport activity of tetraethylammonium from l-carnitine in rat renal brush-border membranes. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1609, 218-224.	1.4	7
140	Evaluation of the Potency of Telaprevir and Its Metabolites as Inhibitors of Renal Organic Cation Transporters, a Potential Mechanism for the Elevation of Serum Creatinine. Drug Metabolism and Pharmacokinetics, 2014, 29, 266-271.	1.1	7
141	Valacyclovir-Induced Acute Kidney Injury in Japanese Patients Based on the PMDA Adverse Drug Reactions Reporting Database. Therapeutic Innovation and Regulatory Science, 2015, 49, 81-85.	0.8	5
142	Decreased cellular toxicity of neomycin in a clonal cell line isolated from LLC-PK1. Pharmaceutical Research, 1993, 10, 573-576.	1.7	4
143	Kinetic analysis of p-aminohippurate transport in the OK kidney epithelial cell line. Pharmaceutical Research, 2000, 17, 1155-1157.	1.7	4
144	Independent organic cation transport activity of Na⁺-<scp>l</scp>-carnitine cotransport system in LLC-PK₁ cells. American Journal of Physiology - Renal Physiology, 2001, 281, F273-F279.	1.3	4

#	Article	IF	Citations
145	Effects of arbekacin and vancomycin on release of lactate dehydrogenase and fragmentation of DNA in LLC-PK1 kidney epithelial cells. Pharmaceutical Research, 1999, 16, 1132-1135.	1.7	3
146	Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2. European Journal of Pharmaceutical Sciences, 2021, 158, 105666.	1.9	3
147	Modulation of organic cation transport and lipid fluidity by benzyl alcohol in rat renal brush-border membranes. Pharmaceutical Research, 1996, 13, 1069-1072.	1.7	2
148	Time-saving multiplex detection of single nucleotide polymorphisms by ultrasensitive DNA microarray. Journal of Biochemistry, 2010, 148, 557-563.	0.9	2
149	Telaprevir-Induced Renal Adverse Events in Japanese Patients Reported in the PMDA Adverse Drug Reactions Reporting Database. Therapeutic Innovation and Regulatory Science, 2016, 50, 355-360.	0.8	2
150	Pharmacological and Toxicological Significance of the Organic Cation Transporters OCT and MATE: Drug Disposition, Interaction and Toxicity. , 2016, , 73-92.		2
151	Effect of neutral endopeptidase inhibition on the natriuresis and renal clearance of atrial natriuretic peptide in perfused rat kidney. Pharmaceutical Research, 1998, 15, 1499-1502.	1.7	1
152	Interaction of Azole Antifungal Agents with Human P-glycoprotein Expressed in a Kidney Epithelial Cell Line, LLC-PK1.. Drug Metabolism and Pharmacokinetics, 2001, 16, 5-11.	0.0	1
153	The Globalization of JSSX DMPK Progress in Research. Drug Metabolism and Pharmacokinetics, 2010, 25, 319.	1.1	0
154	Analysis of Regulatory Mechanisms for Tubular Secretion of Organic Cations by Cultured Renal Cells. Drug Metabolism and Pharmacokinetics, 1993, 8, 719-722.	0.0	0